DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Low Dose hCG in the Late Follicular Phase

Information source: Universitair Ziekenhuis Brussel
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: human chorionic gonadotropin (Drug); recombinant gonadotropins (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Universitair Ziekenhuis Brussel

Official(s) and/or principal investigator(s):
Christophe Blockeel, MD, Principal Investigator, Affiliation: UZ Brussel, Centre for Reproductive Medicine, Brussels


In this study,the investigators compared two protocols for controlled ovarian hyperstimulation in infertility patients requiring IVF. In the control group, the patient undergoes a standard antagonist protocol. In the study group, the administration of gonadotropins is stopped in the late follicular phase and replaced by low dose human chorionic gonadotropins. The primary endpoint of the study is the number of oocytes retrieved in both groups.

Clinical Details

Official title: Among ICSI Patients Undergoing Antagonist Protocols With Recombinant FSH, Does Replacement of Recombinant FSH by 200 IU of hCG in the Late Follicular Phase Compared With Continuing Recombinant FSH, Result in a Similar Number of Oocytes?

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Number of oocytes in both treatment groups

Secondary outcome: Duration of stimulation in both treatment groups, amount of gonadotropins consumed in each treatment group


Minimum age: 18 Years. Maximum age: 36 Years. Gender(s): Female.


Inclusion Criteria:

- < 36 years on day of randomisation

- FSH < 12 in the early follicular phase

- Normal ultrasound scan

- BMI between 18 and 29 (both inclusive)

- Randomisation at outpatient clinic

Exclusion Criteria:

- Endometriosis ≥ grade 3

- PCO syndrome

- Poor responder

- Endocrine or metabolic abnormalities

Locations and Contacts

UZ Brussel, Laarbeeklaan 101, Brussels 1090, Belgium
Additional Information

Related publications:

Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005 Aug;84(2):394-401.

Starting date: September 2007
Last updated: October 8, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017